Duke University Medical Center, Durham, NC Assistant Professor, Department of Internal Medicine
Research Focus: Immunotherapy, Cancer Vaccine
Cancer Type: Melanoma
Award: Young Investigator
Melanoma has been steadily increasing in recent years and despite improvements in diagnosis and early stage treatment, metastatic cancer patients have less than a 10% prognosis for recovery. Dr. Hanks is studying pathways that block the immune system’s ability to destroy cancers. These fundamental pathways, which are present in many cancers, inhibit potent dendritic cells that would otherwise open the door to an immune system attack. This research has identified a fatty acid transporter that plays a crucial role in this process and the possibility of a drug intervention that will shut down the barrier to treatment. Based on these findings, and laboratory research, Dr. Hanks has proposed to engineer a vaccine that will genetically silence the inhibitor so the body’s natural killer T-cells can do their job. Grant funding will support further testing to confirm the effect of the transporter, with the intent to develop a vaccine treatment primarily for melanoma.
Dr. Hanks has dedicated the last decade to research in the fields of tumor immunology and immunotherapy. He served as Fellow and Resident at Duke University Medical Center, Durham, NC, after earning an MD in Medicine and a PhD in Cancer Immunology at Baylor College of Medicine in Houston, TX. He has published extensively and has received numerous awards for his work.Return to Fellows List